Compare NGVC & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NGVC | OMER |
|---|---|---|
| Founded | 1955 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Food Chains | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 744.4M | 628.9M |
| IPO Year | 2012 | 2009 |
| Metric | NGVC | OMER |
|---|---|---|
| Price | $24.90 | $12.52 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $32.50 |
| AVG Volume (30 Days) | 271.1K | ★ 4.4M |
| Earning Date | 02-05-2026 | 11-13-2025 |
| Dividend Yield | ★ 2.37% | N/A |
| EPS Growth | ★ 36.05 | N/A |
| EPS | ★ 2.00 | N/A |
| Revenue | ★ $1,330,836,000.00 | N/A |
| Revenue This Year | $7.83 | N/A |
| Revenue Next Year | $6.97 | N/A |
| P/E Ratio | $12.67 | ★ N/A |
| Revenue Growth | ★ 7.19 | N/A |
| 52 Week Low | $23.47 | $2.95 |
| 52 Week High | $61.22 | $17.65 |
| Indicator | NGVC | OMER |
|---|---|---|
| Relative Strength Index (RSI) | 41.61 | 50.47 |
| Support Level | $23.47 | $11.85 |
| Resistance Level | $25.95 | $16.14 |
| Average True Range (ATR) | 0.89 | 1.62 |
| MACD | 0.25 | -0.37 |
| Stochastic Oscillator | 51.40 | 43.31 |
Natural Grocers by Vitamin Cottage Inc operates natural and organic grocery and dietary supplement stores. It offers the following product categories, natural and organic food, dietary supplements, natural body care, household, pet care products, books and handouts. The Company has a single reporting segment, natural and organic retail stores, through which business are conducted. The company generates the majority of its revenue from grocery products and dietary supplements and rest from other products.
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.